RE: Trying to be fair9 Aug 2024 18:59
Hi Tech,
I mean this was always going to be the way with an LDT being our first test, but having a company in the US aggressively pursuing profit, it'd be no surprise to see BIO hit there forecasts of $30m+ in revs in year end April '27. Some may say that's too long to wait, well that's up to them.
In normal market conditions the market would value us a lot higher than today with the main value being the IP, but, of course, we probably wouldn't have hit the lows we're at so it's all relative really. I'd just hoped by now we'd have moved up a level, 3-4p range, £15-20m mc, out of this nasty rut below 2p. The next few months may change that, but i probably said the same thing 12 months ago when we'd all believed we were more advanced in our journey and that launch would be this year.
As far as other tests go, i still can't find any which are close to market. In all honesty, until AI begins to play its role against stage 1 cancer of any kind ( 2040s, maybe late 2030s at a push), biomarker tests are the key. I still feel 3 years after listing we still stand alone in this market (as long as the trials go as expected).
With OBD, totally crowded market, the prostate space and incomparable to us. In many ways they remind me of the likes of ODX in the Covid testing space. Developed a sound product, opened the doors and shouted it to the world as if it's a case that the big companies and organisations come chasing you for your product. Most of the hard yards in securing partnerships has been done during the development stages and I see no reason as of yet to doubt those in the US with their website, LinkedIn activity etc. But we shall see.
Sign In
Follow the stocks
